Connect with us

Technology

Molecular Instruments and Visiopharm Announce Strategic Partnership to Combine AI-Driven Precision Pathology with HCR™ Pro Assays to Advance Clinical-Grade RNA-ISH

Published

on

LOS ANGELES, Nov. 6, 2024 /PRNewswire/ — Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, is pleased to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology software. This collaboration brings together MI’s clinical-grade HCR™ platform with Visiopharm’s Oncotopix® Discovery software, empowering users with a highly flexible, deep learning approach to precise and efficient image analysis for RNA-ISH assays.

MI’s class-leading HCR™ Pro RNA-ISH assay, lauded for making protease-free sample preparation the standard for RNA-ISH, provides unparalleled specificity and sensitivity in RNA detection and enables seamless integration with existing IHC/IF workflows. When combined with Oncotopix® Discovery, researchers can analyze chromogenic and fluorescent HCR™ Pro RNA-ISH and HCR™ Pro RNA-ISH + IHC/IF co-detection images with more precise segmentation and spot counting, ensuring accurate gene expression profiling in even the most challenging samples.

“Our North Star at MI is to set bioimaging assays to a true ‘clinical-grade’ standard, focusing on performance, robustness, and accessibility,” said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. “Partnering with Visiopharm reflects our shared drive to delivering clinical-grade assays, paired with world-class analysis tools that empower pathologists and support downstream decision-making. We’re thrilled to kickstart this journey with the team at Visiopharm to bring new possibilities to RNA-ISH.”

Visiopharm’s Oncotopix® Discovery software enables users to explore complex tissue data intuitively and customize analyses to fit their specific experimental needs. Its advanced exploratory capabilities enhance analysis accuracy in complex tissue samples. The ability to develop custom deep-learning-based segmentation algorithms, which can account for both cellular and nuclear morphology, enables more precise quantification of RNA. This marks a significant improvement over traditional methods, which often struggle with complex or irregular structures, such as a nuclear or multinucleate cells, leading to missed or inaccurate counts.

“At Visiopharm, our mission is to empower researchers with advanced tools that deliver unmatched precision in image analysis,” said Regan Baird, Senior Vice President, Commercial Strategy Deployment of Visiopharm. “Partnering with Molecular Instruments allows us to elevate the standard of RNA-ISH analysis, integrating our Oncotopix® Discovery software with MI’s HCR™ technology to provide researchers with an unprecedented level of accuracy and efficiency. We are excited to collaborate and advance the field of precision pathology, accelerating breakthroughs in disease research and diagnostics.”

This partnership marks a pivotal advancement in research, combining high-performance, clinical-grade RNA-ISH with sophisticated image analysis. Together, we are equipping scientists to drive breakthroughs in disease studies, offering deeper insights into gene expression and protein interactions. By integrating our innovative technologies, we aim to accelerate discoveries across translational medicine, where accurately and precisely understanding gene and protein expression are essential.

About Molecular Instruments: 
Molecular Instruments® (www.hcrimaging.com) develops and synthesizes molecular kits powered by the breakthrough HCR™ imaging platform for applications in academic research, drug development, synthetic biology, and clinical pathology and diagnostics.

About Visiopharm: 
Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
For more information visit visiopharm.com.

Media Contact: Joyce Yoo, Associate Director of Marketing, joyce@molecularinstruments.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/molecular-instruments-and-visiopharm-announce-strategic-partnership-to-combine-ai-driven-precision-pathology-with-hcr-pro-assays-to-advance-clinical-grade-rna-ish-302297058.html

SOURCE Molecular Instruments

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Oberon Securities Advises Keens Steakhouse in Sale Transaction

Published

on

By

Oberon Securities acted as exclusive advisor to Keens Steakhouse in the sale transaction.

NEW YORK, Nov. 23, 2024 /PRNewswire-PRWeb/ — Oberon Securities, a New York-based middle market investment banking firm, acted as exclusive advisor to Keens Steakhouse in the sale transaction announced yesterday.

With more than 70 senior bankers serving businesses across the country and around the world, Oberon is one of the fastest growing New York City based middle-market investment banking firms. Its clients benefit from the market credibility associated with the firm’s longstanding relationships with many of the nation’s largest and most prestigious institutional investors. Oberon’s approach has generated numerous long-term, multi-transaction client engagements and attracted investment bankers who have spent their careers working with middle-market companies.

Media Contact

Steven Alschuler, Oberon Securities, 1 917-647-2151, steve@alschulerpr.com, https://oberonsecurities.com/

View original content to download multimedia:https://www.prweb.com/releases/oberon-securities-advises-keens-steakhouse-in-sale-transaction-302314708.html

SOURCE Oberon Securities; Oberon Securities

Continue Reading

Technology

Specified Technologies Inc. Unveils Firestop Clash Management and Locator Updates

Published

on

By

SOMERVILLE, N.J., Nov. 23, 2024 /PRNewswire/ — Specified Technologies Inc. has announced their latest Firestop Clash Management (FCM) and Firestop Locator (FSL) releases. FCM automates the process of locating and assigning firestop solutions to conditions within Autodesk® Revit®, enabling firestop novices to find firestop solutions like a firestop expert. In this latest release, STI has further expanded the capabilities of FCM by integrating it with their firestop documentation and compliance tool, Firestop Locator (FSL). FSL enables contractors and facilities’ teams to document the status, location, and products used for any and all fire life safety services across a building.

In the latest update for FSL, teams can now create custom items to track any service on their project beyond the base six (Penetration, Joint, Extinguisher, Door, Damper, and Barrier). Teams can also modify the base six items to include project specific inspection and maintenance requirements and any other details that they would like to be tracked.

With this new integration, decisions made during the design phase of a building using FCM are seamlessly passed into FSL during the construction phase, giving implementation teams a jump start on work to be done. This integration also improves data integrity and eliminates the guesswork in the field of determining what firestop systems and products are to be used where.

“We’re proud of the latest releases of FCM and FSL and look forward to continuing to support the fire life safety community,” says Justin Pine, Sr. Manager of Software & Services.

Specified Technologies Inc. promotes life and building safety by developing innovative fire protection systems and accompanying digital tools that help stop the spread of fire, smoke, and hot gases. Our SpecSeal® and EZ Path® product lines are engineered for easy installation and deliver powerful performance, often resulting in lower installed costs. Since firestopping is our only business, we concentrate all our resources on providing the highest quality, fully tested, innovative firestopping solutions.

Contact: Jess Bern; jbern@stifirestop.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/specified-technologies-inc-unveils-firestop-clash-management-and-locator-updates-302314629.html

SOURCE Specified Technologies, Inc.

Continue Reading

Technology

ZICC: Internet Experts Pay Attention to the Development of Artificial Intelligence

Published

on

By

BEIJING, Nov. 23, 2024 /CNW/ — During the Wuzhen Summit of the World Internet Conference, ZICC interviewed Internet experts from all over the world.

Lampros Sterg, UNESCO Chair in AI & Data Science, said that AI can accelerate social progress, but it needs to be used properly to avoid its negative effects in order to benefit citizens and society. Latif Ladid, the president of the IPv6 Forum, called for the establishment of a global governance system to allow artificial intelligence technology to serve humanity for good. South Korean computer scientist Kilnam Chon shared insights on AI’s positive role in healthcare. He urged global efforts to ensure AI safety and prevent its misuse in weapons. Indian entrepreneur Bibin Babu said he believes that AI will not replace humans, but will create more new jobs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/zicc-internet-experts-pay-attention-to-the-development-of-artificial-intelligence-302314745.html

SOURCE ZICC

Continue Reading

Trending